Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Hempdocon Jun 28, 2020 11:30pm
186 Views
Post# 31201574

RE:RE:RE:RE:RE:New Paper on TLD-1433 and Lung Cancer

RE:RE:RE:RE:RE:New Paper on TLD-1433 and Lung Cancer

vestor111 wrote: WOW! WOW! WOW! Incredible find Eogan!   Just catching up.

I believe the therapy being proposed is a topical application which may mean it is already covered by the NMIBC Ph1b trial.  (GBM would probably require an IV instillation and may require it's own Ph1b.)  

If this assumption is correct about being a topical application and covered already by the Ph1b trial for NMIBC...a NSCLC trial could progress fairly rapidly and it sound like it might be a very low cost to pursue.  

This could be quite huge - fast to trial and low cost to execute with a knowledgeable and willing US partner.   

 

This is huge Vestor...& the plan IS to instill a saline solution of TLD-1433 directly into the thoracic cavity.  I agree...the similar drug delivery has the potential to significantly expedite an NSCLC trial by accelerating a Ph 1 or possibly skipping it altogether, especially if TLD dosage & laser frequency are ultimately similar to those used in NMIBC.  Not sure if the different indication makes a significant difference here, but that's what a pre-IND consultation is for.  Good luck...

Bullboard Posts